Skip to main content
SpringerLink
Log in

Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial

  • IM - ORIGINAL
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Portal vein thrombosis (PVT) and acute variceal bleeding (AVB) are frequent complications of cirrhosis. The efficacy, safety, and timing of anticoagulant treatment in cirrhotic patients with PVT and AVB are contentious issues. We aimed to establish the safety and efficacy of initiating nadroparin calcium–warfarin sequential (NWS) anticoagulation therapy early after esophageal variceal band ligation within PVT patients having cirrhosis and AVB. Cirrhotic patients having AVB and PVT who underwent EVL were included and randomly allocated to either the NWS therapy group (1-month nadroparin calcium by subcutaneous injection following 5-month warfarin through oral administration, n = 43) or the control group (without any anticoagulation therapy, n = 43). The primary endpoint was the rate of PVT recanalization. Secondary endpoints included major bleeding events mainly referring to variceal rebleeding (5-day failure, 14-day, 4-week, 6-week, and 6-month rebleeding rates) and mortality after EVL. The overall recanalization (complete and partial) rate in the NWS therapy group was significantly higher than that in the control group (67.4% vs. 39.5%, P = 0.009). Low Child–Pugh score (P = 0.039, OR: 0.692, 95% CI 0.488–0.982), D-dimer < 2.00 ug/mL (P = 0.030, OR: 3.600, 95% CI 1.134–11.430), and NWS anticoagulation therapy (P = 0.002, OR: 4.189, 95% CI 1.660–10.568) were the predictors of PVT recanalization through univariate analysis of binary logistic regression. NWS anticoagulation therapy (P = 0.003, OR: 4.506, 95% CI 1.687–12.037) was the independent factor of recanalization through multivariate analysis. Nobody bled except for variceal rebleeding. Five-day failure and 14-day rebleeding were zero. There were no significantly different in 4-week (2.3% vs. 4.7%, P = 1.000), 6-week (4.7% vs. 9.3%, P = 0.672) and 6-month rebleeding (18.6% vs. 20.9%, P = 0.787) between the two groups. There was no mortality during six months follow-up. Low serum albumin (P = 0.011, OR: 0.844, 95% CI 0.741–0.962), high MELD score (P = 0.003, OR: 1.564, 95% CI 1.167–2.097) and Child–Pugh score (P = 0.006, OR: 1.950, 95% CI 1.206–3.155) were predictors of rebleeding by univariate analysis of binary logistic regression analysis. The Child–Pugh score (7 [6–8] vs. 6 [5–7], P = 0.003) and albumin levels (33.93 ± 5.30 vs. 37.28 ± 4.32, P = 0.002) were improved in the NWS therapy group at six months. In PVT patients with cirrhosis and AVB, starting NWS anticoagulation therapy early after EVL was safe and effective. It has the potential to raise albumin levels and improve liver function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zhao Y, Ren M, Lu G et al (2020) The prognosis analysis of liver cirrhosis with acute variceal bleeding and validation of current prognostic models: a large scale retrospective cohort study. Biomed Res Int 2020:1–7

    Google Scholar 

  2. Kovacs TOG, Jensen DM (2019) Varices. Clin Liver Dis 23:625–642

    Article  PubMed  Google Scholar 

  3. Qi X, Su C, Ren W et al (2015) Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: a systematic review of the literature. Clin Res Hepatol Gas 39:683–691

    Article  Google Scholar 

  4. Gao Z, Zhao J, Liu X et al (2021) Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case-control study. Hepatol Int 15:1183–1195

    Article  PubMed  Google Scholar 

  5. Zhou T, Sun X, Zhou T et al (2020) Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: a randomized controlled trial. Clin Transl Gastroen 11:e228

    Article  Google Scholar 

  6. Hayashi T, Takatori H, Horii R et al (2019) Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. Bmc Gastroenterol 19:217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Noronha Ferreira C, Reis D, Cortez-Pinto H et al (2019) Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis. Digest Dis Sci 64:2671–2683

    Article  CAS  PubMed  Google Scholar 

  8. Rodriguez-Castro KI, Vitale A, Fadin M et al (2019) A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroen Hepat 31:34–42

    Article  Google Scholar 

  9. Scheiner B, Stammet PR, Pokorny S et al (2018) Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr 130:446–455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. EASL Clinical Practical Guidelines (2016) Vascular diseases of the liver. J Hepotol 64:179–202

    Article  Google Scholar 

  11. de Franchis R, Bosch J, Garcia-Tsao G et al (2022) Baveno VII–Renewing consensus in portal hypertension. J Hepatol 76:959–974

    Article  PubMed  Google Scholar 

  12. Wiesner R (2001) MELD and PELD: application of survival models to liver allocation. Liver Transplant 7:567–580

    Article  CAS  Google Scholar 

  13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649

    Article  CAS  PubMed  Google Scholar 

  14. Sarin SK, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, Valla DC (2016) Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology 151:574–577

    Article  PubMed  Google Scholar 

  15. Angelo Luca M, Settimo Caruso M, Mariapina Milazzo M et al (2012) Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology 265:124–132

    Article  PubMed  Google Scholar 

  16. Tajiri T, Yoshida H, Obara K et al (2010) General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Digest Endosc 22:1–9

    Article  Google Scholar 

  17. Sarin SK, Lahoti D, Saxena SP et al (1992) Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology (Baltimore, MD) 16:1343–1349

    Article  CAS  PubMed  Google Scholar 

  18. Hanafy AS, Abd-Elsalam S, Dawoud MM (2019) Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vasc Pharmacol 113:86–91

    Article  CAS  Google Scholar 

  19. Loffredo L, Pastori D, Farcomeni A, Violi F (2017) Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 153:480–487

    Article  CAS  PubMed  Google Scholar 

  20. Dueñas E, Cachero A, Amador A et al (2020) Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis. Digest Liver Dis 52:79–83

    Article  Google Scholar 

  21. Krige J, Spence RT, Jonas E et al (2020) A new recalibrated four-category Child-Pugh score performs better than the original Child-Pugh and MELD scores in predicting in-hospital mortality in decompensated alcoholic cirrhotic patients with acute variceal bleeding: a real-world cohort analysis. Wrld J Surg 44:241–246

    Article  Google Scholar 

  22. Tantai X, Liu N, Yang L et al (2019) Prognostic value of risk scoring systems for cirrhotic patients with variceal bleeding. World J Gastroentero 25:6668–6680

    Article  CAS  Google Scholar 

  23. Fortune BE, Garcia-Tsao G, Ciarleglio M et al (2017) Child-Turcotte-Pugh class is best at stratifying risk in variceal hemorrhage. J Clin Gastroenterol 51:446–453

    Article  PubMed  PubMed Central  Google Scholar 

  24. Carvalho JR, Machado MV (2018) New insights about albumin and liver disease. Ann Hepatol 17:547–560

    Article  CAS  PubMed  Google Scholar 

  25. Pettinari I, Vukotic R, Stefanescu H et al (2019) Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol 114:258–266

    Article  CAS  PubMed  Google Scholar 

  26. Cui S, Shu R, Yan S et al (2015) Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroentrol Hepat 27:914–919

    Article  CAS  Google Scholar 

  27. Yan Zhang BXXW, Zhong-ji Meng YGZQ, Shang HLSW et al (2020) Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. Clin Gastroenterol H 18:2564–2572

    Article  Google Scholar 

  28. Dai J, Qi X, Li H, Guo X (2015) Role of D-dimer in the development of portal vein thrombosis in liver cirrhosis: a meta-analysis. Saudi J Gastroentero 21:165–174

    Article  Google Scholar 

  29. Naymagon L, Tremblay D, Zubizarreta N et al (2021) Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. Dig Dis Sci 66:3619–3629

    Article  CAS  PubMed  Google Scholar 

  30. Trebicka J, Gu W, Ibanez-Samaniego L et al (2020) Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. J Hepatol 73:1082–1091

    Article  PubMed  Google Scholar 

  31. Lv Y, Qi X, He C et al (2018) Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut 67:2156–2168

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

There is no financial support of this study.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, People’s Republic of China

    Zhanjuan Gao, Jinhou Li & Yanjing Gao

  2. Department of Gastroenterology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China

    Zhanjuan Gao, Shanshan Li & Jingrun Zhao

  3. Department of Gastroenterology, Taian City Central Hospital, Taian, Shandong, People’s Republic of China

    Jinhou Li

Authors
  1. Zhanjuan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shanshan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingrun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinhou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanjing Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yanjing Gao.

Ethics declarations

Conflict of interest

Zhanjuan Gao, Shanshan Li, Jingrun Zhao, Jinhou Li, Yanjing Gao declare that there is no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Human and animal rights

The study was approved by the local Ethical Committee.

Informed consent

Patients gave informed consent to participate.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, Z., Li, S., Zhao, J. et al. Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial. Intern Emerg Med 18, 513–521 (2023). https://doi.org/10.1007/s11739-023-03206-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-023-03206-x

Keywords

Search

Navigation